APA (7th ed.) Citation

D. Lynn Kirkpatrick, Cari Evans, Linda A. Pestano, Jeffrey Millard, Matthew Johnston, Emily Mick, & William K. Schmidt. (2024). Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers. Wiley.

Chicago Style (17th ed.) Citation

D. Lynn Kirkpatrick, Cari Evans, Linda A. Pestano, Jeffrey Millard, Matthew Johnston, Emily Mick, and William K. Schmidt. Clinical Evaluation of PF614, a Novel TAAP Prodrug of Oxycodone, Versus OxyContin in a Multi‐ascending Dose Study with a Bioequivalence Arm in Healthy Volunteers. Wiley, 2024.

MLA (9th ed.) Citation

D. Lynn Kirkpatrick, et al. Clinical Evaluation of PF614, a Novel TAAP Prodrug of Oxycodone, Versus OxyContin in a Multi‐ascending Dose Study with a Bioequivalence Arm in Healthy Volunteers. Wiley, 2024.